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Hepatitis C virus (HCV) is the major etiologic agent of non-A, non-B hepatitis. One of the difficulties in developing anti-
HCV drugs is the lack of an efficient HCV cultivation system. We have generated an artificial surrogate virus suitable for
testing the antiviral effects of drugs affecting HCV protease NS3, an enzyme believed to be essential for HCV proliferation.
The surrogate virus genome is composed of most of the poliovirus genome and HCV protease NS3 and an NS3-specific
cleavage site. The activity of HCV protease NS3 is required for proliferation of this chimeric virus. The antiviral efficacy of
HCV protease inhibitors can, therefore, be evaluated by examining the effects of the drugs on the surrogate virus proliferation.
q 1996 Academic Press, Inc.
INTRODUCTION is cleaved by an HCV-encoded metalloprotease, which
resides between the C-terminal portion of NS2 and the
Hepatitis C virus (HCV) is the major etiologic agent of N-terminal region of NS3 (Grakoui et al., 1993b; Hijikata
non-A, non-B hepatitis (Alter et al., 1989; Choo et al., et al., 1993). The cleavage of the NS3/4A, NS4A/4B,
1989; Kuo et al., 1989). This virus is also known to be NS4B/5A, and NS5A/5B sites depends on the activity of
implicated in liver cirrhosis and hepatocellular carcinoma the serine protease NS3 (Bartenschlager et al., 1993;
(Bruix et al., 1989; Saito et al., 1990). Currently, the sole Eckart et al., 1993; Grakoui et al., 1993a; Han et al., 1995;
treatment for HCV patients involves a-interferon. How- Hijikata et al., 1993; Tomei et al., 1993). HCV protease
ever, only about one-half of the patients respond to some NS3 is a good putative therapeutic target molecule for
extent to the a-interferon treatment (Hino et al., 1994; the development of anti-HCV drugs, since its activity is
Tsubota et al., 1994). Development of other anti-HCV considered essential for viral proliferation. Protease ac-
drugs is, therefore, highly desirable. tivity of NS3 resides in the N-terminal part of NS3 (Bar-
HCV belongs to the family Flaviviridae, whose mem- tenschlager et al., 1994; Han et al., 1995; Lin et al., 1994),
bers are enveloped viruses having a positive-sense RNA and NS4A enhances the protease activity of NS3 (Bar-
genome (Francki et al., 1991; Inchauspe et al., 1991; tenschlager et al., 1994; Failla et al., 1994; Hahm et al.,
Miller and Purcell, 1990; Takamizawa et al., 1991). The 1995; Lin et al., 1995; Tanji et al., 1995). Characterization
RNA encodes a polyprotein (3010 amino acids) with the of the NS3 protease using known protease inhibitors has
following gene order: 5*-C-E1-E2-NS2-NS3-NS4A-NS4B- revealed that NS3 is a chymotrypsin-like protease (Hahm
NS5A-NS5B-3*. During and/or after synthesis, the poly- et al., 1995).
protein is processed into functional proteins by host- and Poliovirus is the prototype of picornaviruses. The po-
virus-encoded proteases. Core protein (C) and envelope lioviral genome is composed of a positive-sense single-
proteins (E1 and E2) are believed to compose the struc- stranded RNA molecule that encodes a single open read-
tural elements of the virion particle. The signal peptidase ing frame (ORF) (Kitamura et al., 1981; Racaniello and
on the endoplasmic reticulum is responsible for the gen- Baltimore, 1981). Upon infection, the genomic RNA is
eration of the N-terminus of E1, E2, and possibly NS2 translated into a large precursor polyprotein via the inter-
(Harada et al., 1991; Hijikata et al., 1991; Hsu et al., 1993; nal ribosomal entry site (IRES) in the 5* nontranslated
Matsuura et al., 1992; Mizushima et al., 1994; Spete et al., region of the RNA (Jang et al., 1988; Pelletier and Sonen-
1992). It has been suggested that the NS2/NS3 junction berg, 1988). The polyprotein, in turn, is processed into
the mature viral structural and nonstructural proteins by
the 2A, 3C, and 3CD proteases (Harris et al., 1991; Law-1 To whom correspondence and reprint requests should be ad-
son and Semler., 1990). Poliovirus is one of the bestdressed at Department of Life Science, Pohang University of Science
studied viruses and is relatively easy to manipulate andand Technology, San31, Hyoja Dong, Pohang, Kyungbuk 790-784, Ko-
rea. Fax: 82(562)279-2199. E-mail: sungkey@vision.postech.ac.kr. cultivate. Production of infectious poliovirus from cDNA
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clones has been practiced for a decade to study func- phorylated with polynucleotide kinase and then digested
with EcoRI. pNS3DC-4A-PV1 was cleaved with SacI,tions of polioviral proteins (Molla et al., 1991; Racaniello
and Baltimore, 1981; Van der Werf et al., 1986) or for use treated with T4 DNA polymerase, and then digested with
EcoRI. The larger fragment of pNS3DC-4A-PV1 was li-of the poliovirus as a vector in delivering foreign genes
into host cells (Alexander et al., 1994; Andino et al., 1994; gated to the PCR product to generate pNS3DC-PV1. The
junction sequences were confirmed by sequencing.Lu et al., 1995). Recently, chimeric polioviruses con-
taining translational control elements of HCV have been
reported (Lu and Wimmer, 1996). Site-directed mutagenesis of the serine in the
In this report, we describe the use of the poliovirus’s catalytic triad of the HCV protease (Ser1165Ala)
versatility in developing a surrogate virus suitable for the
Site-directed mutagenesis was carried out by the Kun-investigation of HCV protease activity. We generated a
kel method as previously described (Kunkel et al., 1987).new hybrid virus containing the whole poliovirus open
pSK1016-1650 was generated by ligation of the DNA frag-reading frame which supports virus replication and virus
ments isolated from PvuII plus SalI-digested pTHE1016-particle formation and is preceded by the protease do-
1846 and SmaI plus SalI-digested pBluescript SK(/).main of HCV NS3 and one of its target sequences. The
Escherichia coli strain RZ1032 (ung0 dut0) was trans-protease activity of the enzyme NS3 is required for viabil-
formed with pSK1016-1650, and ssDNA was preparedity of the hybrid virus.
from the transformant. An oligonucleotide, 5*-CTTGAA-
GGGCTCCGCGGGTGG-3*, designed to change the ser-MATERIALS AND METHODS
ine residue in the catalytic triad of HCV protease to ala-
Construction of plasmids nine [Ser1165(TCG) to Ala(GCG)] was used for site-di-
rected mutagenesis. The base change was confirmed byDNA manipulations were carried out by standard
the presence of a newly generated SacII site and bymethods (Sambrook et al., 1989). The construction of the
sequencing. pSK1016-1650 (Ser1165 Ala) was used toplasmids pTHED1219-1634 and pPNENPO are de-
construct pNS3DC*-PV1 by replacing the XmaI fragmentscribed elsewhere (Han et al., 1995; Alexander et al.,
of pNS3DC-PV1 with the same fragment of pSK1016-1994). pUC19 was cleaved with XbaI, treated with
1650 (Ser1165Ala).Klenow, and digested with PstI. The resulting 2.6-kb frag-
ment was then ligated to the 1.3-kb fragment of
In vitro transcription and translationpTHED1219-1634 treated with NcoI, Klenow, and PstI in
succession. The result was the construct pUC19- Plasmid DNAs were purified following the polyethyl-
NS3DC-4DC. pPNENPO and pUC19-NS3DC-4DC were ene glycol precipitation method. RNAs were transcribed
digested with EcoRI or KpnI, respectively, and treated from the purified DNAs with T7 RNA polymerase (Boeh-
with Klenow enzyme. The linearized DNAs were ligated ringer Mannheim) as described by the manufacturer.
to result in the construct pPNENPO-NS3DC-4DC. These RNA transcripts were translated in a rabbit reticu-
To construct pNS3DC-4A-PV1, a polymerase chain re- locyte lysate system (RRL) supplemented with 25% HeLa
action (PCR) was performed using the following four oli- cell lysate in the presence of [35S]methionine. The in vitro
gonucleotides: primer 1, 5*-TGATATCGAATTCCGG-3*; translation reactions were carried out at 307 for 8 hr. The
primer 2, 5*-ATATGAGCTCCGCACTCTTCCATCTC-3*; 35S-labeled proteins were analyzed on 15% SDS–PAGE
primer 3, 5*-ATATGAGCTCAGGTTTCATCACAGAAAG-3*; using the buffer system described by Nicklin et al. (1987).
primer 4,5*-CTGTGCTAGCGCTTTTTG-3*. Primers 1 and The intensity of the autoradiographic images was en-
2 and pPNENPO-NS3DC-4DC were used to amplify the hanced by fluorography using salicylic acid. Gels were
HCV protease NS3DC-4A region (PCR product 1). PCR dried and exposed to Kodak XAR-5 film or Agfa Curix
product 1 contains a new SacI site immediately after the RP1 film.
NS4A-coding sequence. Primers 3 and 4 and pPNENPO
were used to amplify polioviral cDNA (746-2479) with a RNA transfection
new SacI site at the beginning of the poliovirus ORF (PCR
product 2). EcoRI- and NheI-digested pPNENPO, EcoRI- An electroporation protocol was used to transfect
HeLa cell monolayers with the viral RNAs prepared inand SacI-digested PCR product 1, and SacI- and NheI-
digested PCR product 2 were ligated together to gener- vitro. Cells grown to 80% confluency were harvested.
After two washes, the cells were resuspended in theate plasmid pNS3DC-4A-PV1.
To construct pNS3DC-PV1, an oligonucleotide (5*- medium at a concentration of 5 1 106 cells/ml. The cell
suspension (1 ml) was mixed with 3 mg of RNA andAGCTCCGCAGCAGACGACGTCCTCACTGGCTTCCTC
TTGCGCGCCTCCTCCTCCGGTTGAGTTATCTGTGA placed in a 0.4-cm Gene Pulser cuvette (Bio-Rad). The
cuvette was electrically pulsed at 360 V and 960 mF usingAGAC-3*) encoding the C-terminal end of NS5A (P1-P10)
and primer 1 were used to amplify the HCV region encod- the Gene Pulser transfection apparatus (Bio-Rad). Then
the cells were diluted with 9 ml of medium containinging amino acids 1016–1215. The PCR product was phos-
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10% bovine calf serum, 5% equine serum, and 5% fetal
calf serum.
Plaque assay and one-step growth curve
Titers of virus stocks were measured by plaque assay
on HeLa cell monolayers as follows. Cells were inocu-
lated with virus, left for 30 min at room temperature, and
then overlaid with Eagle’s medium containing 0.9% Noble
agar and 5% fetal calf serum. Viral plaques were visual-
ized with 0.5% crystal violet solution 60 hr postinfection.
To measure one-step growth kinetics, virus was
loaded onto 3.5-cm HeLa cell plates at a multiplicity of
infection of 10 per cell and incubated at room tempera-
ture for 30 min to allow virus binding. Unbound particles
were removed by two rounds of PBS washing. The in-
fected cells were cultured at 377 in 2 ml of Eagle’s me-
dium containing 10% bovine calf serum and harvested at
FIG. 1. Schematic diagram of the genomic organization of poliovirusthe time points indicated in Fig. 5. The infectivity of the
type 1 (Mahoney), NS3DC-PV1, and NS3DC*-PV1. The hatched and
cell lysate at each time point was titrated by plaque open boxes represent HCV protease NS3DC and poliovirus polypro-
assay. tein, respectively. The amino acid sequence at the junction of HCV
protease NS3 and poliovirus P1 is indicated by single-letter amino acid
codes. The target site of HCV protease is marked by an arrowhead.Reverse transcription PCR (RT-PCR)
The mutated amino acid (S1165A) in NS3DC*-PV1 is indicated by an
asterisk.Total RNA from virus-infected cells was isolated 4 hr
postinfection as described by Lu et al. (1995). cDNAs
were synthesized using M-MuLV reverse transcriptase
solution for 3 hr. The antibody was a generous gift fromand oligonucleotide primers corresponding to poliovirus
Dr. R. Bartenschlager, Institute of Virology, Mainz, Ger-nucleotides 556-570 and 789-806 (primer 5: 5*-GTGTTT-
many. A horseradish peroxidase-linked anti-rabbit IgG inCCTTTTATT-3*; primer 6: 5*-CACCATACGCTCTATTTG-
a 1:10,000 dilution was used as the secondary antibody.3*). Primer 5 and primer 6 were used in synthesizing
Membrane-bound antibodies were detected by en-cDNAs from negative- and positive-sense RNA, respec-
hanced chemiluminescence reagents (ECL; Amersham).tively. Both of the primers were used in the PCR that
followed. The PCR products were analyzed on a 1.3%
RESULTSagarose gel.
Generation of a novel poliovirus containing HCV
Labeling of newly synthesized proteins in virus-
protease NS3 and its target site
infected cells
In order to develop an evaluation system for anti-HCV
HeLa cells were infected with poliovirus 1 (Mahoney:
drugs targeting protease NS3, we constructed a recombi-
PV1) and vNS3DC-PV1 at a multiplicity of infection of 30
nant poliovirus that requires the activity of HCV protease
PFU per cell. The cells were incubated in a medium
for its proliferation. A schematic diagram of the genomic
lacking methionine for 10 min 3 hr after infection. Subse-
structure of this virus is depicted in Fig. 1. In the case
quently, 100 mCi of [35S]methionine was added to the
of polyprotein NS3DC-PV1, the protease domain of HCV
medium and the incubation continued for 40 min. The
NS3 is fused to the last 10 amino acids of NS5A (EEA-
cells were then collected and lysed. The lysate was ana-
SEDVVCC), which are recognized by protease NS3.
lyzed on 15% SDS–PAGE.
These amino acid residues are preceded by four gly-
cines, alanine, and glutamine serving as a hinge regionImmunoblot analysis
between the protease domain and the target site.
NS3DC is the 188 N-terminal amino acids of the HCVVirus-infected cells were lysed 4 hr postinfection. Total
protein (13 mg) was resolved on a 15% SDS–PAGE gel NS3 protein. We expected that the HCV protease NS3
would cleave the peptide bond between cysteine at theand transferred onto a nitrocellulose membrane (Amer-
sham). The blot was incubated overnight at 47 in blocking C-terminus of the additional polypeptide and glycine at
the N-terminus of poliovirus P1, since HCV protease NS3solution [20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5%
Tween 20, and 5% powdered skim milk] to block nonspe- is known to cleave between the cysteine or threonine at
the P1 residue and the small uncharged residues at thecific binding. The primary antibody (polyclonal antibody
against HCV protease NS3) was added to the blocking P1* residue (Kolykhalov et al., 1994; Komoda et al., 1994).
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FIG. 2. Plaque phenotypes of PV1(M) (left) and vNS3DC-PV1 (right). HeLa cells were infected with fifth-passage stocks of PV1(M) or vNS3DC-
PV1. Plaque assays were carried out 60 hr postinfection.
Upon transfection, the RNA transcript encoding Proper proteolytic processing of vNS3DC-PV1
polyprotein requires HCV NS3 protease activityNS3DC-PV1 produced a virus designated vNS3DC-PV1.
On the other hand, the RNA transcript similar to NS3DC-
Proteolytic processing patterns of polyproteins en-PV1 but containing a serine-to-alanine mutation at the
coded by poliovirus, NS3DC-PV1, and NS3DC*-PV1 RNAcatalytic triad of HCV protease NS3 (NS3DC*-PV1) did
were analyzed by in vitro transcription and translation ofnot yield virus. This strongly suggests that HCV protease
pT7-PV1, pNS3DC-PV1, and pNS3DC*-PV1. Most of theNS3 activity is essential for the viability of the hybrid
polioviral proteins were detected as in vitro translationvirus vNS3DC-PV1. This is expected since PV needs
products of the PV1 RNA transcript (Fig. 4A, lane 1). Twoan authentic N-terminus of the P1 capsid precursor for
additional protein bands of 123 and 26 kDa were appar-myristoylation of the capsid protein VP4 (Chow et al.,
ent among the translation products of NS3DC-PV1 com-1987; Paul et al., 1987). The virus vNS3DC-PV1 has a
small plaque phenotype at 377 as shown in Fig. 2 (com-
pare plaque sizes in panel PV1 with vNS3DC-PV1) or at
307 (data not shown).
The virus vNS3DC-PV1 is stable through at least five
passages. The integrity of vNS3DC-PV1 was confirmed
by analyzing the viral RNAs in cells inoculated with a
virus stock of the fourth passage. The inserted HCV se-
quence in the poliovirus genome was amplified by RT-
PCR with primers annealing to the poliovirus 5* nontrans-
lated region and the P1-coding region. The viral RNAs of
the fifth passage retained the inserted HCV protease and
NS5A sequences as shown in Fig. 3. Both positive and
negative sense viral RNAs of the expected sizes were
detected (Fig. 3, lanes 2 and 3, respectively). RT-PCR
analysis of the genomic RNAs isolated from vNS3DC-
PV1 virion particles revealed the same RT-PCR products
as the RNAs isolated from HeLa cells (data not shown).
FIG. 3. RT-PCR analysis of vNS3DC-PV1 RNA. HeLa cells were in-The junction sequence between HCV and poliovirus was
fected with fourth-passage stocks of vNS3DC-PV1, and total RNA was
confirmed by DNA sequencing of the PCR products (data isolated from the cells. Lanes 1, 2, and 3 depict DNAs produced by
not shown). This indicates that vNS3DC-PV1 is stable PCR or RT-PCR using as templates plasmid pNS3DC-PV1, (/) sense
RNA, and (0) sense RNA, respectively.for at least five passages.
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FIG. 4. Proteolytic processing patterns of PV1, NS3DC-PV1, and NS3DC*-PV1 polyproteins. (A) In vitro translation products of RNAs transcribed
from pT7-PV1, pNS3DC-PV1, and pNS3DC*-PV1. Translation reactions were performed in rabbit reticulocyte lysate supplemented with HeLa cell
extract in the presence of [35S]methionine and RNA transcribed from pT7-PV1 (lane 1), pNS3DC-PV1 (lane 2), or pNS3DC*-PV1 (lane 3). Labeled
proteins were analyzed on a 15% polyacrylamide gel. Poliovirus-specific proteins and HCV protease NS3-related proteins are indicated on the right
side of the panel. (B) In vivo labeling of newly synthesized proteins in HeLa cells infected with PV1 or vNS3DC-PV1. HeLa cells were labeled with
[35S]methionine for 40 min at 3 hr postinfection. Lanes 1, 2, and 3 show [35S]methionine-labeled proteins of mock-, PV1-, and vNS3DC-PV1-infected
cells, respectively. (C) Detection of HCV NS3-related proteins by immunoblot analysis. Virus-infected HeLa cells were lysed 4 hr postinfection, and
Western blot analysis was performed with antibody against HCV NS3. Lanes 1, 2, and 3 show the Western results of mock-, PV1-, and vNS3DC-
PV1-infected cells, respectively.
pared to the PV1 translation products (Fig. 4A, lane 2). N-terminus of P1 that has been shown to be important
in the processing of P1 by poliovirus protease 3C-3DThe 123- and 26-kDa proteins are most likely the NS3DC-
P1 fusion protein and the processed NS3DC, respec- (Kra¨usslich et al., 1990).
Proteolytic processing was also investigated for PV1tively, since the cleavage of poliovirus at the P1/P2 junc-
tion occurs very quickly, even during the process of and vNS3DC-PV1 by labeling newly synthesized proteins
with [35S]methionine in virus-infected cells. In compari-translation. Translation of NS3DC*-PV1 also yielded the
123-kDa protein. However, the cleavage products of the son to PV1-infected cells, the labeling pattern in
vNS3DC-PV1-infected cells showed four additionalfusion polypeptide, the 26-kDa protein, and the P1 protein
were not detected among the translation products from bands with apparent molecular weights of 123, 89, 63,
and 26 kDa, as indicated by arrowheads (Fig. 4B, com-this construct (Fig. 4A, lane 3). This indicates that proteo-
lytic cleavage of the HCV/poliovirus junction does not pare lane 2 with lane 3). These proteins are most likely
NS3DC-P1, NS3DC-VP0-VP3, NS3DC-VP0, and NS3DC,occur in NS3DC*-PV1 and that the cleavage of this junc-
tion is mediated by the protease activity of NS3. It also respectively (Fig. 4B). This assumption is supported by
the Western blotting analysis using an antibody againstshows that the failure of virus production with the
NS3DC*-PV1 construct is most likely due to the lack of HCV NS3 and HeLa cell extracts after infection with ei-
ther wild-type poliovirus or vNS3DC-PV1 (Fig. 4C).the P1 polypeptide which is a protein processed into viral
coat protein (VP0, VP1, and VP3). In other words, HCV Among the proteins of vNS3DC-PV1-infected cells, the
anti-NS3 antibody recognized the 63- and the 26-kDaNS3 activity is essential for proliferation of the vNS3DC-
PV1. Interestingly, significant generation of the viral cap- polypeptides corresponding to NS3DC-VP0 and NS3DC,
respectively (Fig. 4C, lane 3). A longer exposure of thesid proteins (VP0, VP1, and VP3) from the NS3DC*-PV1
polyprotein was not detected. On the other hand, the X-ray film also revealed the 123-kDa band and the 89-
kDa band corresponding to NS3DC-P1 and NS3DC-VP0-processed capsid proteins were apparent along with the
precursor NS3DC-P1 in construct NS3DC-PV1 (compare VP3, respectively (data not shown). On the other hand,
no bands were detected in the Western analysis of celllane 2 with lane 3 in Fig. 4A). The blockage of proteolytic
processing of the NS3DC*-PV1 polyprotein may be due extracts from wild-type poliovirus- or mock-infected cells
(Fig. 4C, lanes 1 and 2). The results indicate that proteo-to the lack of myristoylation of the glycine residue at the
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hepatitis, liver cirrhosis, and hepatocellular carcinoma.
In the absence of vaccines, the development of anti-
HCV drugs is, therefore, urgent. One of the difficulties in
developing anti-HCV drugs is the lack of an efficient HCV
cultivation system. In vitro HCV cultivation systems avail-
able to date are inefficient and technically difficult to
manipulate (Yoo et al., 1995; Beach et al., 1993; Shimizu
et al., 1992). Moreover, only very low HCV titers are ob-
served even in sera of hepatitis patients. This may sug-
gest that naturally, HCV replicates at very low rates. If
this is the case, development of proper surrogate viruses
incorporating specific aspects of HCV is called for by
investigators who want to study HCV genes in virus repli-
cation or want to test antiviral efficacy of drugs affecting
HCV-encoded enzymes.
We have generated a novel virus vNS3DC-PV1 which
is suitable for testing the activity of HCV protease NS3.
FIG. 5. One-step growth curves of PV1(M) and vNS3DC-PV1. HeLa This virus is composed, sequentially, of a partially de-
cells were infected with either PV1 or vNS3DC-PV1 at a multiplicity of leted segment of the poliovirus 5*NTR, the HCV NS3
infection of 10. Cells were harvested at the time points indicated, and
protease domain plus a NS3-specific cleavage site, thethen the virus titers were determined by plaque assay.
complete polioviral polyprotein-coding region, and the
3*NTR of the poliovirus. The 5*NTR of poliovirus contains
cis-acting elements required for viral RNA replicationlytic processing of the artificial polyprotein occurs as
(Rohll et al., 1994) and for translation of viral mRNA via anexpected. The relative intensities of the NS3-related
IRES (Pelletier and Sonenberg, 1988). The nonconservedbands varied depending on the methodologies used to
sequence in the 5*NTR, which lies between the poliovirusdetect the polypeptides. For instance, a strong band of
IRES and the initiating AUG, was deleted to reduce theNS3DC-P1 was detected by in vitro and in vivo labeling,
size of the viral genome. This nonconserved region wasbut only a weak band of NS3DC-P1 was detected by
shown to be dispensable in an in vitro cultivation systemWestern blot analysis. The [35S]methionine labeling
(Kuge and Nomoto, 1987). In all, the genome of vNS3DC-method reveals only newly synthesized polypeptides,
PV1 is 7320 nucleotides long, an increase of 10.5% overand larger proteins, containing more methionine resi-
the wild-type genome. Such an increase has previouslydues, give stronger signals. Western blot analysis, on
been shown to be tolerated in poliovirus replication, atthe other hand, reveals all of the proteins interacting
least for low passaged virus (Alexander et al., 1994).with the primary antibody, and the intensity of the signal
The HCV protease NS3 and its target site (the C-termi-reflects the molarities of the proteins rather than their
nal 10 amino acids of NS5A) were added to the N-termi-size. Therefore, [35S]methionine labeling methods are ex-
nus of the complete poliovirus polyprotein. In otherpected to give relatively stronger signals for precursor
words, the cysteine residue at the C-terminus of HCVforms than Western blot analysis methods.
protein is followed by the glycine residue of the N-termi-
One-step growth kinetics of chimeric virus nus of polioviral polyprotein (Fig. 1). In this configuration,
vNS3DC-PV1 the protease NS3DC cleaves the HCV/poliovirus junction
as shown in Fig. 4. We cannot determine whether theWe obtained the one-step growth curve for vNS3DC-
HCV/poliovirus junction is cleaved in cis or in trans byPV1 (Fig. 5). While maximum production of wild-type po-
HCV protease. Nevertheless, this chimeric virus will beliovirus was reached 4 hr postinfection (Fig. 5, open
useful in testing the efficacy of antiviral drugs based onsquares), that of vNS3DC-PV1 was delayed by about 2
protease inhibition, since HCV NS3 has both cis (NS3/hr (Fig. 5, closed circles). The titer of vNS3DC-PV1 at the
4A junction) and trans cleavage (NS4A/4B, NS4B/5A, andpeak was about 1.5 log units lower than that of wild-type
NS5A/5B junctions) activities. It has been well docu-poliovirus (Fig. 5, compare viral titers at 9 hr postinfec-
mented that HCV protease NS3 alone can cleave thetion). The small plaque phenotype of vNS3DC-PV1 may
NS5A/5B junction although addition of NS4A enhancesthus be a result of delayed virion particle formation and
the NS3 protease activity. We have tried to constructsmaller burst size.
another hybrid virus containing both NS3DC and 4A to-
gether (NS3DC-4A), since it promised stronger protease
DISCUSSION
activity than NS3DC alone (Hahm et al., 1995). However,
this construct did not yield virus. The reason is unknown.HCV exhibits a high infection rate worldwide (1–2% of
the population), causing severe liver diseases such as Perhaps encapsidation of the genomic RNA may have
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been hampered by the limiting size of the poliovirus cap- requires HCV protease NS3 activity for viability. We ex-
pect that this virus will be valuable in antiviral efficacysid. The additional 189 nucleotides of NS4A, in addition
to the extra 711 nucleotides of NS3DC, may be too much testing of drugs aimed at protease NS3. This virus will
also provide a tool in studying the possible roles of NS3to accommodate in the viral RNA encapsidation. More
likely, NS3DC-4A may be toxic to cellular function(s) by in virus replication such as induction or blockage of host
cell apoptosis, selective translation of viral mRNAs, andmodifying cellular protein(s). We have previously de-
tected toxicity of NS3DC-4A in our preliminary study in host cell transformation.
tissue culture cells. Specifically, whereas we could es-
tablish a HeLa cell line producing NS3DC, we could ACKNOWLEDGMENTS
not do so for NS3DC-4A (Lee and Jang, unpublished
We are indebted to Dr. Bartenschlager for the supply of antibodyobservation). The highly hydrophobic domain in NS4A
against HCV NS3. The present studies were supported in part by grants
may be the cause of the toxic effect. from the G7 program, Ministry of Science and Technology, and from
Several lines of evidence suggest that the hybrid virus KOESEF through SRC for cell differentiation, and by Grant BSRI-94-
4434 from the Ministry of Education.vNS3DC-PV1 needs HCV protease activity for its viability.
First, a single amino acid change from serine to alanine
in the catalytic triad of HCV protease in NS3DC-PV1 REFERENCES
abolished virus production, as seen in the RNA transfec-
Alexander, L., Lu, H.-H., and Wimmer, E. (1994). Polioviruses containingtion of construct pNS3DC*-PV1. In vitro translation prod-
picornavirus type 1 and/or type 2 internal ribosomal entry site ele-
ucts of the RNA transcribed from pNS3DC*-PV1, which ments: Genetic hybrids and the expression of a foreign gene. Proc.
maintains the HCV and poliovirus junction site and intact Natl. Acad. Sci. USA 91, 1406–1410.
Alter, H. J., Purcell, R. H., Shih, J. W., Melpolder, J. C., Houghton, M.,poliovirus proteases, showed no cleavage between HCV
Choo, Q.-L., and Kuo, G. (1989). Detection of antibody to hepatitis Cand the poliovirus P1 polypeptides (Fig. 4A, lane 3). In
virus in prospectively followed transfusion recipients with acute andcontrast, processing of the HCV NS3-P1 fusion polypep-
chronic non-A non-B hepatitis. N. Engl. J. Med. 321, 1494–1500.
tide was apparent in the translation products of NS3DC- Andino, R., Silvera, D., Suggett, S. D., Achacoso, P. L., Miller, C. J., Balti-
PV1 RNA transcripts containing active, wild-type prote- more, D., and Feinberg, M. B. (1994). Engineering poliovirus as a
vaccine vector for the expression of diverse antigens. Science 265,ase NS3-coding sequence (Fig. 4A, lane 2). This strongly
1448–1451.suggests that the proteolytic processing of the HCV/po-
Ansardi, D. C., Porter, D. C., and Morrow, C. D. (1992). Myristylation ofliovirus junction of the vNS3DC-PV1 polypeptides is me-
poliovirus capsid precursor P1 is required for assembly of subviral
diated by HCV protease NS3. The in vitro translation data particles. J. Virol. 66, 4556–4563.
also make unlikely the possibility that the cleavage of Bartenschlager, R., Ahlborn-Laake, L., Mous, J., and Jacobsen, H. (1993).
Nonstructural protein 3 of the hepatitis C virus encodes a serine-typethe HCV/poliovirus junction in vNS3DC-PV1 is mediated
protease required for cleavage at the NS3/4 and NS4/5 junctions. J.by a cellular protease, or by one of the polioviral prote-
Virol. 67, 3835–3844.ases. Second, the cleavage must be precise to produce
Bartenschlager, R., Ahlborn-Laake, L., Mous, J., and Jacobsen, H. (1994).
viable virus, and HCV NS3 is the most probable protease Kinetic and structural analyses of hepatitis C virus polyprotein pro-
for the cleavage. The N-terminal amino acid residue of cessing. J. Virol. 68, 5045–5055.
Beach, M. J., Nichols, B. L., Gallagher, M., Humphrey, Jrowczynski, C. K.,the wild-type poliovirus polyprotein (glycine) is myristoy-
and Bradley, D. W. (1993). Tissue culture propagation of hepatitis Clated (Chow et al., 1987; Paul et al., 1987), with the glycine
virus. Abstracts of the International Symposium on Viral Hepatitisresidue being essential for the myristoylation (Marc et al.,
and Liver Disease (The 8th Triennial Congress), Abstract 286, p. 67.
1989). Myristoylation, in turn, is required for proteolytic Viral Hepatitis Research Foundation of Japan, Tokyo.
processing of P1 (Kra¨usslich et al., 1990) and encapsida- Bruix, J., Calvet, X., Costa, J., Ventura, M., Bruguera, M., Castillo, R.,
Barrera, J. M., Ercilla, G., Sanchez-Tapias, J. M., Vall, M., Bru, C., andtion of the genomic RNA (Ansardi et al., 1992). Polioviral
Rodes, J. (1989). Prevalence of antibodies to hepatitis C virus inprotease is unlikely to be involved in the precise cleav-
Spanish patients with hepatocellular carcinoma and hepatic cirrho-age, since the polioviral proteases differ in their substrate
sis. Lancet ii, 1004–1006.
specificities from those of HCV protease NS3. One of the Choo, Q.-L., Kuo, G., Weiner, A. J., Bradley, L. R. D. W., and Houghton,
major protease target site-determining parameters is the M. (1989). Isolation of a cDNA clone derived from a blood-borne non-
A non-B viral hepatitis genome. Science 244, 359–362.amino acid residues near the scissile bond. For instance,
Chow, M., Newman, J. F., Filman, D., Hogle, J. M., Rowlands, D. J., andfor trans cleavages, poliovirus 2A and 3C prefer TY*G
Brown, F. (1987). Myristylation of picornavirus capsid protein VP4and AXXQ*G as cleavage sites, respectively (Hellen et al.,
and its structural significance. Nature 327, 482–486.
1992; Kra¨usslich and Wimmer, 1988, and the references Eckart, M. R., Selby, M., Masiarz, F., Lee, C., Berger, K., Crawford, K.,
therein), while HCV NS3 prefers cysteine at the P1 resi- Kuo, C., Kuo, G., Houghton, M., and Choo, Q.-L. (1993). The hepatitis
C virus encodes a serine proteinase involved in processing of thedue (Kolykhalov et al., 1994; Komoda et al., 1994; Pizzi et
putative nonstructural proteins from the viral polyprotein precursor.al., 1994). There is no resemblance among the cleavage
Biochem. Biophys. Res. Commun. 192, 399–406.sites of poliovirus and HCV proteases. Therefore, it is
Failla, C., Tomei, L., and De Francesco, R. (1994). Both NS3 and NS4A
not probable that a polioviral protease would functionally are required for proteolytic processing of hepatitis C virus nonstruc-
substitute for HCV protease. tural proteins. J. Virol. 68, 3753–3760.
Francki, R. I. B., Fauquet, C. M., Knudson, D. L., and Brown, F. (1991).In conclusion, the new poliovirus which we generated
AID VY 8265 / 6a23$$$243 11-13-96 15:09:26 vira AP: Virology
325SURROGATE HCV
Classification and nomenclature of viruses: Fifth report of the Interna- Kuge, S., and Nomoto, A. (1987). Construction of viable deletion and
insertion mutants of the Sabin strain of type 1 poliovirus: function oftional Committee on Taxonomy of Viruses. Arch. Virol. 2(Suppl.), 223.
Grakoui, A., McCourt, D. W., Wychowcki, C., Feinstone, S. M., and Rice, the 5* noncoding sequence in viral replication. J. Virol. 61, 1478–
1487.C. M. (1993a). Characterization of the hepatitis C virus-encoded ser-
ine protease: determination of protease-dependent protein cleavage Kunkel, T. A., Roberts, J. D., and Zakour, R. A. (1987). Rapid and efficient
site-specific mutagenesis without phenotypic selection. Methods En-sites. J. Virol. 67, 2832–2843.
Grakoui, A., McCourt, D. W., Wychowcki, C., Feinstone, S. M., and Rice, zymol. 154, 367.
Kuo, G., Choo, Q.-L., Alter, H. L., Gitnick, G. I., Redeker, A. G., Purcell,C. M. (1993b). A second hepatitis C virus-encoded proteinase. Proc.
Natl. Acad. Sci. USA 90, 10583–10587. R. H., Miyamura, T., Dienstag, J. L., Alter, M. J., Stevens, C. E., Tegt-
meier, G. E., Bonino, F., Colombo, M., Lee, W. S., Kuo, C., Berger, K.,Hahm, B., Han, D. S., Back, S. H., Song, O.-K., Cho, M.-J., Kim, C.-J.,
Shimotohno, K., and Jang, S. K. (1995). NS3-4A of hepatitis C virus Shuster, J. R., Overby, L. R., Bradley, D. W., and Houghton, M. (1989).
An assay for circulating antibodies to a major etiologic virus of humanis a chymotrypsin-like protease. J. Virol. 69, 2534–2539.
Han, D. S., Hahm, B., Rho, H.-M., and Jang, S. K. (1995). Determination non-A non-B hepatitis. Science 244, 362–364.
Lawson, M. A., and Semler, B. L. (1990). Picornavirus protein-pro-of the protease domain in the hepatitis C virus NS3. J. Gen. Virol.
76, 985–993. cessing enzymes, substrates, and genetic regulation. In ‘‘Current
Topics in Microbiology and Immunology’’ (V. R. Racaniello, Ed.), Vol.Harada, S., Watanabe, Y., Takeuchi, K., Suzuki, T., Katayama, T., Takebe,
Y., Saito, I., and Miyamura, T. (1991). Expression of processed core 161, pp. 49–87. Springer-Verlag, Heidelberg.
Lin, C., Pragai, B. M., Grakoui, A., Xu, J., and Rice, C. M. (1994). Hepatitisprotein of hepatitis C virus in mammalian cells. J. Virol. 65, 3015–
3021. C virus NS3 serine proteinase: Trans-cleavage requirements and
processing kinetics. J. Virol. 68, 8147–8157.Harris, K., Hellen, C. U. T., and Wimmer, E. (1991). Proteolytic pro-
cessing in the replication of picornaviruses. Semin. Virol. 1, 323– Lin, C., Thomson, J. A., and Rice, C. M. (1995). A central region in the
hepatitis C virus NS4A protein allows formation of an active NS3-333.
Hellen, C. U. T., Lee, C.-K., and Wimmer, E. (1988). Determinants of NS4A serine proteinase complex in vivo and in vitro. J. Virol. 69,
4373–4380.substrate recognition by poliovirus 2A proteinase. J. Virol. 66, 3330–
3338. Lu, H.-H., Alexander, L., and Wimmer, E. (1995). Construction and ge-
netic analysis of dicistronic polioviruses containing open readingHijikata, M., Mizushima, H., Akagi, T., Mori, S., Kakiuchi, N., Kato, N.,
Tanaka, T., Kimura, K., and Shimotohno, K. (1993). Two distinct prote- frames for epitopes of human immunodeficiency virus type 1 gp120.
J. Virol. 69, 4797–4806.ase activities required for the processing of a putative nonstructural
precursor protein of hepatitis C virus. J. Virol. 67, 4665–4675. Lu, H.-H., and Wimmer, E. (1996). Poliovirus chimeras replicating under
the translational control of genetic elements of hepatitis C virusHijikata, M., Kato, N., Ootsuyama, Y., Nakagawa, M., and Shimotohno,
K. (1991). Gene mapping of the putative structural region the hepatitis reveal unusual properties of the internal ribosomal entry site of hepa-
titis C virus. Proc. Natl. Acad. Sci. USA 93, 1412–1417.C virus genome by in vitro processing analysis. Proc. Natl. Acad.
Sci. USA 88, 5547–5551. Marc, D., Drugeon, G., Haenni, A. L., Girard, M., and van der Werf, S.
(1989). Role of myristoylation of poliovirus capsid protein VP4 asHino, K., Sainokami, S., Shimoda, K., Iino, S., Wang, Y., Okamoto, H.,
Miyakawa, Y., and Mayumi, M. (1994). Genotypes and titers of hepati- determined by site-directed mutagenesis of its N-terminal sequence.
EMBO J. 8, 2661–2668.tis C virus for predicting response to interferon in patients with
chronic hepatitis C. J. Med. Virol. 42, 299–305. Matsuura, Y., Harada, S., Suzuki, R., Watanabe, Y., Inoue, Y., Saito, I.,
and Miyamura, T. (1992). Expression of processed envelope proteinHsu, H. H., Donets, M., Greenberg, H., and Feinstone, S. M. (1993).
Characterization of hepatitis C virus structural proteins with a recom- of hepatitis C virus in mammalian and insect cells. J. Virol. 66, 1425–
1431.binant baculovirus expression system. Hepatology 17, 763–771.
Inchauspe, G., Zebedee, S., Lee, D.-H., Sugitani, M., Nasoff, M., and Miller, R. H., and Purcell, R. H. (1990). Hepatitis C virus shares amino
acid sequence similarity with pestiviruses and flaviviruses as wellPrince, A. M. (1991). Genomic structure of the human prototype strain
H of hepatitis C virus: Comparison with the American and Japanese as members of two plant virus supergroups. Proc. Natl. Acad. Sci.
USA 87, 2057–2061.isolates. Proc. Natl. Acad. Sci. USA 88, 10292–10296.
Jang, S. K., Kra¨usslich, H.-G., Nicklin, M. J. H., Duke, G. M., Palmenberg, Mizushima, H., Hijikata, M., Tanji, Y., Kimura, K., and Shimotohno, K.
(1994). Analysis of N-terminal processing of hepatitis C virus non-A. C., and Wimmer, E. (1988). A segment of the 5* nontranslated
region of encephalomyocarditis virus RNA directs internal entry of structural protein 2. J. Virol. 68, 2731–2734.
Molla, A., Paul, A. V., and Wimmer, E. (1991). Cell-free, de novo synthe-ribosomes during in vitro translation. J. Virol. 62, 2636–2643.
Kitamura, N., Semler, B. L., Rothberg, P. G., Larsen, G. R., Adler, C. J., sis of poliovirus. Science 254, 1647–1651.
Nicklin, M. J. H., Kra¨usslich, H.-G., Toyoda, H., Dunn, J. J., and Wimmer,Dorner, A. J., Emini, E. A., Hanecak, R., Lee, J. J., van der Werf, S.,
Anderson, C. W., and Wimmer, E. (1981). Primary structure, gene E. (1987). Poliovirus polypeptide precursors: Expression in vitro and
processing by exogenous 3C and 2A proteases. Proc. Natl. Acad.organization and polypeptide expression of poliovirus RNA. Nature
(London) 291, 547–553. Sci. USA 84, 4002–4006.
Paul, A. V., Schultz, A., Pincus, S. E., Oroszlan, S., and Wimmer, E. (1987).Kolykhalov, A. A., Agapov, E. V., and Rice, C. M. (1994). Specificiety of
the hepatitis C virus NS3 serine protease: Effects of substitutions at Capsid protein VP4 of poliovirus is N-myristoylated. Proc. Natl. Acad.
Sci. USA 84, 7827–7831.the 3/4A, 4A/4B, 4B/5A, and 5A/5B cleavage sites on polyprotein
processing. J. Virol. 68, 7525 – 7533. Pelletier, J., and Sonenberg, N. (1988). Internal initiation of translation
of eucaryotic mRNA directed by a sequence derived from poliovirusKomoda, Y., Hijikata, M., Sato, S., Asabe, S.-I., Kimura, K., and Shimo-
tohno, K. (1994). Substrate requirements of hepatitis C virus serine RNA. Nature (London) 334, 320–325.
Pizzi, E., Tramontano, A., Tomei, L., La Monica, N., Failla, C., Sardana,proteinase for intermolecular polypeptide cleavage in E. coli. J. Virol.
68, 7351–7357. M., Wood, T., and De Francesco, R. (1994). Molecular model of the
specificity pocket of the hepatitis C virus protease: Implications forKra¨usslich, H.-G., and Wimmer, E. (1988). Viral proteinases. Annu. Rev.
Biochem. 57, 701–754. substrate recognition. Proc. Natl. Acad. Sci. USA 91, 888–892.
Racaniello, V. R., and Baltimore, D. (1981). Molecular cloning of poliovi-Kra¨usslich, H.-G., Holscher, C., Reuer, Q., Harber, J., and Wimmer, E.
(1990). Myristoylation of the poliovirus polyprotein is required for rus cDNA and determination of the complete nucleotide sequence
of the viral genome. Proc. Natl. Acad. Sci. USA 78, 4887–4891.proteolytic processing of the capsid and for viral infectivity. J. Virol.
64, 2433–2436. Rohll, J. B., Percy, N., Ley, R., Evans, D. J., Almond, J. F., and Barclay,
AID VY 8265 / 6a23$$$244 11-13-96 15:09:26 vira AP: Virology
326 HAHM ET AL.
W. S. (1994). The 5*-untranslated regions of picornavirus RNAs con- Onishi, E., Andoh, T., Yoshida, I., and Okayama, H. (1991). Structure
and organization of the hepatitis C virus genome isolated from humantain independent functional domains essential for RNA replication
carrier. J. Virol. 65, 1105–1113.and translation. J. Virol. 68, 4384–4391.
Tanji, Y., Hijikata, M., Satoh, S., Kaneko, T., and Shimotohno, K. (1995).Saito, I., Miyamura, T., Ohbayashi, A., Harada, H., Katayama, T., Kikuchi,
Hepatitis C virus-encoded nonstructural protein NS4A has versatileS., Watanabe, Y., Koi, S., Onji, M., Ohta, Y., Choo, Q.-L., Houghton,
functions in viral protein processing. J. Virol. 69, 1575–1581.M., and Kuo, G. (1990). Hepatitis C virus infection is associated with
Tomei, L., Failla, C., Santolini, E., De Francesco, R., and La Monica, N.the development of hepatocellular carcinoma. Proc. Natl. Acad. Sci.
(1993). NS3 is a serine protease required for processing of hepatitisUSA 87, 6547–6549.
c virus polyprotein. J. Virol. 67, 4017–4026.Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). ‘‘Molecular Cloning:
Tsubota, A., Chayama, K., Ikeda, K., Yasuji, A., Koida, I., Saitoh, S.,A Laboratory Manual,’’ 2nd ed. Cold Spring Harbor Laboratory Press,
Hashimoto, M., Iwasaki, S., Kobayashi, M., and Hiromitsu, K. (1994).
Cold Spring Harbor, NY.
Factors predictive of response to interferon-alpha therapy in hepatitis
Shimizu, Y. K., Iwamoto, A., Hijikata, M., Purcell, R. H., and Yoshikura, C virus infection. Hepatology 19, 1088–1094.
H. (1992). Evidence for in vitro replication of hepatitis C virus genome Van der Werf, S., Bradely, J., Wimmer, E., Studier, F. W., and Dunn, J. J.
in a human T-cell line. Proc. Natl. Acad. Sci. USA 89, 5477–5481. (1986). Synthesis of infectious poliovirus RNA by purified T7 RNA
Spaete, R. R., Alexander, D., Rugroden, M. E., Choo, Q.-L., Berger, K., polymerase. Proc. Natl. Acad. Sci. USA 83, 2330–2334.
Crawford, K., Kuo, C., Leng, S., Lee, C., Ralston, R., Thudium, K., Yoo, B. J., Selby, M. J., Choe, J., Suh, B. S., Choi, S. H., Joh, J. S., Nuovo,
Tung, J. W., Kuo, G., and Houghton, M. (1992). Characterization of G. J., Lee, H.-S., Houghton, M., and Han, J. H. (1995). Transfection
the hepatitis E2/NS1 gene product expressed in mammalian cells. of a differentiated human hepatoma cell line (Huh7) with in vitro-
Virology 188, 819–830. transcribed hepatitis C virus (HCV) RNA and establishment of a long-
term culture persistently infected with HCV. J. Virol. 69, 32–38.Takamizawa, A., Mori, C., Fuke, I., Manabe, S., Murakami, S., Fujita, J.,
AID VY 8265 / 6a23$$$244 11-13-96 15:09:26 vira AP: Virology
